Takako Yoshii

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 926 citations · Full text

Medicine, Oncology, Pharmacology +17

Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck

Chikatoshi Katada, Tomonori Yano, Kazuhiro Kaneko et al. · Gastroenterology · 2016 · 210 citations · Full text

Medicine, Oncology, Otolaryngology +15

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2019 · 69 citations

Medicine, Oncology, Pharmacology +16

Long-term outcome of endoscopic resection for intramucosal esophageal squamous cell cancer: a secondary analysis of the Japan Esophageal Cohort study

Ichiro Oda, Yuichi Shimizu, Toshiyuki Yoshio et al. · Endoscopy · 2020 · 54 citations · Full text

Medicine, Oncology, Surgery +13

Alcohol abstinence and risk assessment for second esophageal cancer in Japanese men after mucosectomy for early esophageal cancer

Akira Yokoyama, Chikatoshi Katada, Tomonori Yano et al. · PLoS ONE · 2017 · 29 citations · Full text

Medicine, Oncology, Cancer Epidemiology +11